Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TK1 | P04183 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744345 | 1.00 | ABL1 (0.41) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL3813740 | 0.80 | LMNA (0.41) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL10521119 | 0.79 | TYMP (0.32) | ABL1RIN1 | |
| SCHEMBL10481879 | 0.79 | LMNA (0.37) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL10481880 | 0.79 | LMNA (0.37) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL6757643 | 0.78 | LMNA (0.36) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL6757641 | 0.78 | LMNA (0.36) | ABL1RIN1LMNAALBALDH1A1 | |
| Phosphoric Acid SCHEMBL9086402 | 0.77 | TK1 (0.39) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL23797137 | 0.77 | ABL1 (0.46) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL6632471 | 0.77 | ABL1 (0.46) | ABL1RIN1LMNAALBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| US-20040146893-A1 | Nucleotide sequences coding heterologous polypeptide for use in diagnosis and treatment of nervous system, cell proliferative, inflammatory and autoimmune diseases; wound healing agents | HUMAN GENOME SCIENCES, INC. (US) | 2004-07-29 | — | — | US | disclosed |
| US-6602664-B2 | Treatment of HIV-infected human in alternation or combination with second anti-HIV drug that induces mutation pattern at other than 70th codon of reverse transcriptase region location; drug resistance, pharmokinetics | EMORY UNIVERSITY | 2003-08-05 | — | — | US | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | disclosed |